Figure 1.

Antibody-based therapeutic strategies for AML: schematic illustration of antibody constructs shown. (I) Anti CD33 conjugated to a toxin (ozogamycin) manufactured as gemtuzumab (12); (II) chimeric antigen receptor T cell using anti CD123 to target myeloid cells (13,14) (not yet in clinical trial); (III) single polypeptide chain bispecific engager antibodies (BiTE) recognizing CD3 and CD3 (15) or CD123 (16); (IV) double polypeptide chain dual affinity retargeting antibodies (DART) recognizing CD3 and CD123 (17,18). AML, acute myelogenous leukemia; VL, light chain; VH, heavy chain; CD3z, zeta chain of CD3; Co-stim, costimulatory molecules.